about
The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's diseaseIron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinson's disease.Motor and cognitive deficits in aged tau knockout mice in two background strains.GSK-3 in Neurodegenerative Diseases.Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOEA delicate balance: Iron metabolism and diseases of the brain.Increased Ndfip1 in the substantia nigra of Parkinsonian brains is associated with elevated iron levels.Metallostasis in Alzheimer's disease.Biometals and their therapeutic implications in Alzheimer's disease.Lithium suppression of tau induces brain iron accumulation and neurodegeneration.Parkinson's disease iron deposition caused by nitric oxide-induced loss of β-amyloid precursor protein.The Complex Role of Apolipoprotein E in Alzheimer's Disease: an Overview and Update.Ferroptosis and cell death mechanisms in Parkinson's disease.Type-1 interferons contribute to the neuroinflammatory response and disease progression of the MPTP mouse model of Parkinson's disease.Elevated plasma ferritin in elderly individuals with high neocortical amyloid-β load.Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse.Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration.α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment.The effect of dopamine on MPTP-induced rotarod disability.Amine oxidase activity of β-amyloid precursor protein modulates systemic and local catecholamine levels.PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease.Serotonergic lesions of the dorsal hippocampus differentially modulate locomotor hyperactivity induced by drugs of abuse in rats: implications for schizophrenia.Nanoscale Imaging Reveals Big Role for Iron in Alzheimer's Disease.Ceruloplasmin and β-amyloid precursor protein confer neuroprotection in traumatic brain injury and lower neuronal iron.S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency.Evidence that iron accelerates Alzheimer's pathology: a CSF biomarker study.Tau-mediated iron export prevents ferroptotic damage after ischemic stroke.Evidence of a Cardiovascular Function for Microtubule-Associated Protein Tau.Association of Cerebrospinal Fluid Ferritin Level With Preclinical Cognitive Decline in APOE-ε4 Carriers.Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export.A comparison of ceruloplasmin to biological polyanions in promoting the oxidation of Fe(2+) under physiologically relevant conditions.The Aβ-induced NFAT apoptotic pathway is also activated by GSK-3 inhibition: implications for Alzheimer therapeutics.Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological DiseasesMarked Age-Related Changes in Brain Iron Homeostasis in Amyloid Protein Precursor Knockout MiceTransferrin protects against Parkinsonian neurotoxicity and is deficient in Parkinson's substantia nigraZn-DTSM, A Zinc Ionophore with Therapeutic Potential for Acrodermatitis Enteropathica?More evidence is needed. Iron, incident cognitive decline and dementia: a systematic reviewAssociation of metals with the risk and clinical characteristics of Parkinson's diseaseIron and Alzheimer's Disease: An Update on Emerging Mechanisms
P50
Q33850971-62A32540-C06C-4EB8-9670-EC165FFAD05BQ33965221-A9826721-BBEE-478D-A7BA-A68B08D1E9CFQ34077327-1CB3A715-2F99-477A-98F3-6EC572BBEB7DQ35001040-898BF537-50A3-46C1-B9BB-48947CC7E8A5Q35775365-4680350E-7521-4212-95FD-1DC80BCF1D01Q37023585-294F598D-9B25-45C1-B46C-4CC43959E999Q37514445-4028E4DC-1DF0-4D76-A393-ED1EC0E381D8Q38059077-33131500-3A11-4F72-B538-F45F58E316D2Q38263669-936848B5-0A43-4DDB-B83B-22FEBFDC2870Q38412707-3A88BA96-42B5-46F3-8276-A77E0AB44936Q38905956-8F05285E-F2B7-4EF8-B7A5-C7AA64F10E59Q38959290-A1609AB7-6CF0-4073-B568-B77C713404A0Q39084397-2F708214-4C9A-4949-B06E-9F9CFEBF85F6Q39609930-73954953-5369-427D-AE37-6192F04FC752Q40139851-A50D1616-FF6D-44AD-B379-C6751B313320Q41183352-AD88CBA6-3F4F-4BC7-BF0A-3ACB4C9F65C8Q41825693-6B8D10B7-7BE7-4934-A79E-2032B16F8A52Q43065145-9881EDB7-F197-4C8E-9390-8B8093B5D6D4Q44752358-7919769F-D9E4-4C8B-8A47-C35318E113B4Q44935800-A79A33B8-F639-4D9E-887D-6AB86239D280Q45300654-490E34D6-8AD7-4B81-8D5D-E5F5B6064BE6Q45921167-836DC3D6-4D20-44B3-B336-948D7A03B689Q46279254-1ED9AF7A-A38B-40F4-8A6A-A0696F95BBB6Q46934259-7EDC9F3A-B843-44F2-AEB7-9C730C1FF577Q47438228-78CE90F8-BCA8-4688-BE16-402EEC05DB21Q47615978-C8CA1C24-5DDE-4420-BE10-D151EBA688D1Q47626563-DA0CB7CE-BFD2-44D0-9ECF-B831EAF38328Q47835893-6268ED3A-69A5-4F7C-97AF-FF2271ED89CFQ47866529-88C67E55-8145-4DEA-AAFB-E433938503DEQ48345542-651ED493-864B-424E-B9DD-F1ECE503F343Q48686425-A57637B8-20D4-4AD6-A6E2-CCA08E52769BQ50626087-EB3C497D-E7BB-44BA-82BF-688E95DEB706Q50749546-9CDD2D78-82F2-4F08-A427-C2B5820BC5E1Q57765818-A3C1BC95-DAB6-4563-992B-85ACFE6E12B8Q58418256-64C50488-D890-4E41-90B9-05C439C59714Q60546002-2CAF7359-BE9C-4DAB-8FE5-E4C849564B6DQ61812627-68427F49-3772-454E-BAE0-06C5EACB4560Q64325279-0086B007-00FD-4E97-A48D-FC988A60E2E3Q64867216-1C0170BA-347E-4DF0-BB2C-F1DACD11A78FQ88978904-E659A749-5CB8-4B87-B73B-C98636328608
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Scott Ayton
@ast
Scott Ayton
@en
Scott Ayton
@es
Scott Ayton
@nl
type
label
Scott Ayton
@ast
Scott Ayton
@en
Scott Ayton
@es
Scott Ayton
@nl
prefLabel
Scott Ayton
@ast
Scott Ayton
@en
Scott Ayton
@es
Scott Ayton
@nl
P1053
J-8000-2015
P106
P1153
35336030100
P31
P496
0000-0002-3479-2427